Astria TherapeuticsATXS
About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Employees: 78
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
64% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 25
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
7% more funds holding
Funds holding: 103 [Q3] → 110 (+7) [Q4]
3.59% more ownership
Funds ownership: 100.22% [Q3] → 103.81% (+3.59%) [Q4]
7% more call options, than puts
Call options by funds: $631K | Put options by funds: $591K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
16% less capital invested
Capital invested by funds: $622M [Q3] → $524M (-$98.8M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Wedbush Laura Chico 19% 1-year accuracy 10 / 54 met price target | 447%upside $28 | Outperform Maintained | 12 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 17% 1-year accuracy 56 / 327 met price target | 213%upside $16 | Buy Reiterated | 11 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 67% 1-year accuracy 6 / 9 met price target | 408%upside $26 | Market Outperform Reiterated | 3 Mar 2025 |
JMP Securities Jonathan Wolleben 67% 1-year accuracy 6 / 9 met price target | 408%upside $26 | Market Outperform Initiated | 31 Jan 2025 |
Financial journalist opinion
Based on 3 articles about ATXS published over the past 30 days









